中华皮肤科杂志 ›› 2021, Vol. 54 ›› Issue (12): 1033-1047.doi: 10.35541/cjd.20210643
中华医学会皮肤性病学分会 中国医师协会皮肤科医师分会 中国中西医结合学会皮肤性病专业委员会
收稿日期:2021-09-03
修回日期:2021-10-02
发布日期:2021-12-01
通讯作者:
王刚；张学军
E-mail:xjwgang@fmmu.edu.cn; ayzxj@vip.sina.com
Chinese Society of Dermatology; China Dermatologist Association; Dermatology & Venereology Specialized Committee of Chinese Association of Integrative Medicine
Received:2021-09-03
Revised:2021-10-02
Published:2021-12-01
Contact:
Wang Gang; Zhang Xuejun
E-mail:xjwgang@fmmu.edu.cn; ayzxj@vip.sina.com
摘要： 【摘要】 生物制剂在银屑病治疗中的应用越来越广泛，在治疗中重度、难治性及特殊类型银屑病方面发挥了积极的作用。在我国获批上市并已用于治疗银屑病的生物制剂包括肿瘤坏死因子α抑制剂、白细胞介素12/23抑制剂和白细胞介素17A抑制剂三大类7种制剂，如何合理、有效、安全地使用生物制剂已经成为临床工作中备受关注的问题。为此，我国银屑病诊疗及相关领域专家依据国内外研究数据和临床经验，结合中国银屑病患者的特点，在深入讨论的基础上制订本指南，从生物制剂的应用原则与方法、疗效与安全性、患者的筛查与监测、常见问题与对策以及特殊人群应用的注意事项等方面，为临床医生提供具体的指导意见。
中华医学会皮肤性病学分会 中国医师协会皮肤科医师分会 中国中西医结合学会皮肤性病专业委员会. 中国银屑病生物制剂治疗指南（2021）[J]. 中华皮肤科杂志, 2021,54(12):1033-1047. doi:10.35541/cjd.20210643
Chinese Society of Dermatology, China Dermatologist Association, Dermatology & Venereology Specialized Committee of Chinese Association of Integrative Medicine. Guidelines for the treatment of psoriasis with biologic agents in China （2021）[J]. Chinese Journal of Dermatology, 2021, 54(12): 1033-1047.doi:10.35541/cjd.20210643
| ［1］ | 中华医学会皮肤性病学分会, 中国医师协会皮肤科医师分会, 中国中西医结合学会皮肤性病专业委员会. 中国银屑病生物治疗专家共识（2019）［J］. 中华皮肤科杂志, 2019,52（12）:863⁃871. doi: 10.35541/cjd.20190892. |
| ［2］ | 中华医学会皮肤性病学分会银屑病专业委员会. 中国银屑病诊疗指南（2018简版）［J］. 中华皮肤科杂志, 2019,52（4）:223⁃230. doi: 10.3760/cma.j.issn.0412⁃4030.2019.04.001. |
| ［3］ | Menter A, Strober BE, Kaplan DH, et al. Joint AAD⁃NPF guidelines of care for the management and treatment of psoriasis with biologics［J］. J Am Acad Dermatol, 2019,80（4）:1029⁃1072. doi: 10.1016/j.jaad.2018.11.057. |
| ［4］ | Amatore F, Villani AP, Tauber M, et al. French guidelines on the use of systemic treatments for moderate⁃to⁃severe psoriasis in adults［J］. J Eur Acad Dermatol Venereol, 2019,33（3）:464⁃483. doi: 10.1111/jdv.15340. |
| ［5］ | Smith CH, Yiu Z, Bale T, et al. British Association of Dermatologists guidelines for biologic therapy for psoriasis 2020: a rapid update［J］. Br J Dermatol, 2020,183（4）:628⁃637. doi: 10.1111/bjd.19039. |
| ［6］ | Poelman SM, Keeling CP, Metelitsa AI. Practical guidelines for managing patients with psoriasis on biologics: an update［J］. J Cutan Med Surg, 2019,23（1_suppl）:3S⁃12S. doi: 10.1177/12034 75418811347. |
| ［7］ | Saeki H, Terui T, Morita A, et al. Japanese guidance for use of biologics for psoriasis （the 2019 version）［J］. J Dermatol, 2020,47（3）:201⁃222. doi: 10.1111/1346⁃8138.15196. |
| ［8］ | 黄琼, 杨勤萍, 方栩, 等. 重组人II型肿瘤坏死因子受体⁃抗体融合蛋白治疗寻常性银屑病多中心、随机、双盲实验［J］. 中华皮肤科杂志, 2007,40（11）:655⁃658. |
| ［9］ | Yang HZ, Wang K, Jin HZ, et al. Infliximab monotherapy for Chinese patients with moderate to severe plaque psoriasis: a randomized, double⁃blind, placebo⁃controlled multicenter trial［J］. Chin Med J （Engl）, 2012,125（11）:1845⁃1851. doi: 10. 3760/cma.j.issn.0366⁃6999.2012.11.001. |
| ［10］ | Gottlieb AB, Evans R, Li S, et al. Infliximab induction therapy for patients with severe plaque⁃type psoriasis: a randomized, double⁃blind, placebo⁃controlled trial［J］. J Am Acad Dermatol,2004,51（4）:534⁃542. doi: 10.1016/j.jaad.2004.02.021. |
| ［11］ | Reich K, Nestle FO, Papp K, et al. Infliximab induction and maintenance therapy for moderate⁃to⁃severe psoriasis: a phase III, multicentre, double⁃blind trial［J］. Lancet, 2005,366（9494）:1367⁃1374. doi: 10.1016/S0140⁃6736（05）67566⁃6. |
| ［12］ | Cai L, Gu J, Zheng J, et al. Efficacy and safety of adalimumab in Chinese patients with moderate⁃to⁃severe plaque psoriasis: results from a phase 3, randomized, placebo⁃controlled, double⁃blind study［J］. J Eur Acad Dermatol Venereol, 2017,31（1）:89⁃95. doi: 10.1111/jdv.13746. |
| ［13］ | Menter A, Tyring SK, Gordon K, et al. Adalimumabtherapy for moderate to severe psoriasis: a randomized, controlled phase III trial［J］. J Am Acad Dermatol, 2008,58（1）:106⁃115. doi: 10. 1016/j.jaad.2007.09.010. |
| ［14］ | Gordon K, Papp K, Poulin Y, et al. Long⁃term efficacy and safety of adalimumab in patients with moderate to severe psoriasis treated continuously over 3 years: results from an open⁃label extension study for patients from REVEAL［J］. J Am Acad Dermatol, 2012,66（2）:241⁃251. doi: 10.1016/j.jaad.2010.12.005. |
| ［15］ | Papp K, Thaçi D, Marcoux D, et al. Efficacy and safety of adalimumab every other week versus methotrexate once weekly in children and adolescents with severe chronic plaque psoriasis: a randomised, double⁃blind, phase 3 trial［J］. Lancet, 2017,390（10089）:40⁃49. doi: 10.1016/S0140⁃6736（17）31189⁃3. |
| ［16］ | 刘鸿伟, 胡雪英, 雷东春, 等. 阿达木单抗治疗重度斑块状银屑病的临床观察［J］. 中华皮肤科杂志, 2020,53（9）:744⁃746. doi: 10.35541/cjd.20190757. |
| ［17］ | Lanna C, Zangrilli A, Bavetta M, et al. Efficacy and safety of adalimumab in difficult⁃to⁃treat psoriasis［J］. Dermatol Ther, 2020,33（3）:e13374. doi: 10.1111/dth.13374. |
| ［18］ | Papp KA, Langley RG, Lebwohl M, et al. Efficacy and safety of ustekinumab, a human interleukin⁃12/23 monoclonal antibody, in patients with psoriasis: 52⁃week results from a randomized, double⁃blind, placebo⁃controlled trial （PHOENIX 2） ［J］. Lancet, 2008,371（9625）:1675⁃1684. doi: 10.1016/S0140⁃6736（08）60726⁃6. |
| ［19］ | Philipp S, Menter A, Nikkels AF, et al. Ustekinumab for the treatment of moderate⁃to⁃severe plaque psoriasis in pediatric patients （≥6 to <12 years of age）: efficacy, safety, pharmacokinetic, and biomarker results from the open label CADMUS Jr study［J］. Br J Dermatol, 2020,183（4）:664⁃672. doi: 10.1111/bjd.19018. |
| ［20］ | Blauvelt A, Papp KA, Griffiths CE, et al. Efficacy and safety of guselkumab, an anti⁃interleukin⁃23 monoclonal antibody, compared with adalimumab for the continuous treatment of patients with moderate to severe psoriasis: results from the phase III, double⁃blinded, placebo⁃ and active comparator⁃controlled VOYAGE 1 trial［J］. J Am Acad Dermatol, 2017,76（3）:405⁃417. doi: 10.1016/j.jaad.2016.11.041. |
| ［21］ | Reich K, Armstrong AW, Foley P, et al. Efficacy and safety of guselkumab, an anti⁃interleukin⁃23 monoclonal antibody, compared with adalimumab for the treatment of patients with moderate to severe psoriasis with randomized withdrawal and retreatment: results from the phase III, double⁃blind, placebo⁃ and active comparator⁃controlled VOYAGE 2 trial［J］. J Am Acad Dermatol, 2017,76（3）:418⁃431. doi: 10.1016/j.jaad.2016. 11.042. |
| ［22］ | Reich K, Griffiths C, Gordon KB, et al. Maintenance of clinical response and consistent safety profile with up to 3 years of continuous treatment with guselkumab: results from the VOYAGE 1 and VOYAGE 2 trials［J］. J Am Acad Dermatol, 2020,82（4）:936⁃945. doi: 10.1016/j.jaad.2019.11.040. |
| ［23］ | Deodhar A, Helliwell PS, Boehncke WH, et al. Guselkumab in patients with active psoriatic arthritis who were biologic⁃naive or had previously received TNF⁃α inhibitor treatment （DISCOVER⁃1）: a double⁃blind, randomised, placebo⁃controlled phase 3 trial［J］. Lancet, 2020,395（10230）:1115⁃1125. doi: 10.1016/S0140⁃6736（20）30265⁃8. |
| ［24］ | Mease PJ, Rahman P, Gottlieb AB, et al. Guselkumab in biologic⁃naive patients with active psoriatic arthritis （DISCOVER⁃2）: a double⁃blind, randomised, placebo⁃controlled phase 3 trial［J］. Lancet, 2020,395（10230）:1126⁃1136. doi: 10.1016/S0140⁃6736（20）30263⁃4. |
| ［25］ | Zhuang JY, Li JS, Zhong YQ, et al. Evaluation of short⁃term（16⁃week） effectiveness and safety of guselkumab in patients with psoriasis: a prospective real⁃life study on the Chinese population［J］. Dermatol Ther, 2021:e15054. doi: 10.1111/dth.15054. |
| ［26］ | Cai L, Zhang JZ, Yao X, et al. Secukinumab demonstrates high efficacy and a favorable safety profile over 52 weeks in Chinese patients with moderate to severe plaque psoriasis［J］. Chin Med J （Engl）, 2020,133（22）:2665⁃2673. doi: 10.1097/CM9.000000 0000001163. |
| ［27］ | Huang H, Cai ML, Hong XJ et al. Real⁃world data on the use of secukinumab as treatment for moderate⁃to⁃severe psoriasis in Chinese patients［J］. Eur J Dermatol, 2020,30（5）:554⁃560. doi:10.1684/ejd.2020.3878. |
| ［28］ | Zhao Y, Cai L, Liu XY, et al. Efficacy and safety of secukinumab in Chinese patients with moderate⁃to⁃severe plaque psoriasis: a real⁃life cohort study［J］. Chin Med J （Engl）, 2021,134（11）:1324⁃1328. doi: 10.1097/CM9.0000000000001 510. |
| ［29］ | Gordon KB, Blauvelt A, Papp KA, et al. Phase 3 trials of ixekizumab in moderate⁃to⁃severe plaque psoriasis［J］. N Engl J Med, 2016,375（4）:345⁃356. doi: 10.1056/NEJMoa1512711. |
| ［30］ | Saeki H, Nakagawa H, Nakajo K, et al. Efficacy and safety of ixekizumab treatment for Japanese patients with moderate to severe plaque psoriasis, erythrodermic psoriasis and generalized pustular psoriasis: results from a 52⁃week, open⁃label, phase 3 study （UNCOVER⁃J） ［J］. J Dermatol, 2017,44（4）:355⁃362. doi: 10.1111/1346⁃8138.13622. |
| ［31］ | Nast A, Smith C, Spuls PI, et al. EuroGuiDerm Guideline on the systemic treatment of psoriasis vulgaris ⁃ Part 1: treatment and monitoring recommendations［J］. J Eur Acad Dermatol Venereol, 2020,34（11）:2461⁃2498. doi: 10.1111/jdv.16915. |
| ［32］ | Nast A, Altenburg A, Augustin M, et al. German S3⁃Guideline on the treatment of psoriasis vulgaris, adapted from EuroGuiDerm ⁃ Part 1: treatment goals and treatment recommendations［J］. J Dtsch Dermatol Ges, 2021,19（6）:934⁃150. doi: 10.1111/ddg.14508. |
| ［33］ | Lambert J, Segaert S, Ghislain PD, et al. Practical recommendations for systemic treatment in psoriasis according to age, pregnancy, metabolic syndrome, mental health, psoriasis subtype and treatment history （BETA⁃PSO: Belgian Evidence⁃based Treatment Advice in Psoriasis; part 1）［J］. J Eur Acad Dermatol Venereol, 2020,34（8）:1654⁃1665. doi: 10.1111/jdv. 16684. |
| ［34］ | Lambert JLW, Segaert S, Ghislain PD, et al. Practical recommendations for systemic treatment in psoriasis in case of coexisting inflammatory, neurologic, infectious or malignant disorders （BETA⁃PSO: Belgian Evidence⁃based Treatment Advice in Psoriasis; part 2）［J］. J Eur Acad Dermatol Venereol, 2020,34（9）:1914⁃1923. doi: 10.1111/jdv.16683. |
| ［35］ | de la Cueva Dobao P, Notario J, Ferrándiz C, et al. Expert consensus on the persistence of biological treatments in moderate⁃to⁃severe psoriasis［J］. J Eur Acad Dermatol Venereol, 2019,33（7）:1214⁃1223. doi: 10.1111/jdv.15600. |
| ［36］ | Podoswa⁃Ozerkovsky N, Amaya⁃Guerra M, Barba⁃Gómez JF, et al. Expert recommendations for biological treatment in patients with psoriasis［J］.Gac Med Mex, 2020,156（5）:446⁃453. doi: 10.24875/GMM.M20000441. |
| ［37］ | Lebwohl MG, Kircik L, Callis Duffin K, et al. A randomized study to evaluate the efficacy and safety of adding topical therapy to etanercept in patients with moderate to severe plaque psoriasis［J］. J Am Acad Dermatol, 2013,69（3）:385⁃392. doi: 10.1016/j.jaad.2013.03.031. |
| ［38］ | Richard EG, Hönigsmann H. Phototherapy, psoriasis, and the age of biologics［J］. Photodermatol Photoimmunol Photomed, 2014,30（1）:3⁃7. doi: 10.1111/phpp.12088. |
| ［39］ | Torres AE, Lyons AB, Hamzavi IH, et al. Role of phototherapy in the era of biologics［J］. J Am Acad Dermatol, 2021,84（2）:479⁃485. doi: 10.1016/j.jaad.2020.04.095. |
| ［40］ | Armstrong AW, Bagel J, Van Voorhees AS, et al. Combining biologic therapies with other systemic treatments in psoriasis: evidence⁃based, best⁃practice recommendations from the Medical Board of the National Psoriasis Foundation［J］. JAMA Dermatol, 2015,151（4）:432⁃438. doi: 10.1001/jamadermatol. 2014.3456. |
| ［41］ | Liu LF, Chen JS, Gu J, et al. Etanercept biosimilar （recombinant human tumor necrosis factor⁃α receptor II: IgG Fc fusion protein） and methotrexate combination therapy in Chinese patients with moderate⁃to⁃severe plaque psoriasis: a multicentre, randomized, double⁃blind, placebo⁃controlled trial［J］. Arch Dermatol Res, 2020,312（6）:437⁃445. doi: 10.1007/s00403⁃019⁃02024⁃6. |
| ［42］ | Calzavara⁃Pinton PG, Sala R, Arisi M, et al. Synergism between narrowband ultraviolet B phototherapy and etanercept for the treatment of plaque⁃type psoriasis［J］. Br J Dermatol, 2013,169（1）:130⁃136. doi: 10.1111/bjd.12277. |
| ［43］ | Wolf P, Hofer A, Weger W, et al. 311 nm ultraviolet B⁃accelerated response of psoriatic lesions in adalimumab⁃treated patients［J］. Photodermatol Photoimmunol Photomed, 2011,27（4）:186⁃189. doi: 10.1111/j.1600⁃0781.2011.00594.x. |
| ［44］ | Wolf P, Weger W, Legat FJ, et al. Treatment with 311⁃nm ultraviolet B enhanced response of psoriatic lesions in ustekinumab⁃treated patients: a randomized intraindividual trial［J］. Br J Dermatol, 2012,166（1）:147⁃153. doi: 10.1111/j.1365⁃2133.2011.10616.x. |
| ［45］ | Dalaker M, Bonesrønning JH. Long⁃term maintenance treatment of moderate⁃to⁃severe plaque psoriasis with infliximab in combination with methotrexate or azathioprine in a retrospective cohort［J］. J Eur Acad Dermatol Venereol, 2009,23（3）:277⁃282. doi: 10.1111/j.1468⁃3083.2008.03039.x. |
| ［46］ | Menting SP, van Lümig PP, de Vries AC, et al. Extent and consequences of antibody formation against adalimumab in patients with psoriasis: one⁃year follow⁃up［J］. JAMA Dermatol, 2014,150（2）:130⁃136. doi: 10.1001/jamadermatol.2013.8347. |
| ［47］ | Adişen E, Karaca F, Gürer MA. When there is no single best biological agent: psoriasis and psoriatic arthritis in the same patient responding to two different biological agents［J］. Clin Exp Dermatol, 2008,33（2）:164⁃166. doi: 10.1111/j.1365⁃2230. 2007.02673.x. |
| ［48］ | Krell JM. Use of alefacept and etanercept in 3 patients whose psoriasis failed to respond to etanercept［J］. J Am Acad Dermatol, 2006,54（6）:1099⁃1101. doi: 10.1016/j.jaad.2005.08. 032. |
| ［49］ | Torres T, Tavares Bello R, Paiva Lopes MJ, et al. Portuguese recommendations for the treatment of psoriasis with biologic therapy［J］. Eur J Dermatol, 2020,30（6）:645⁃654. doi: 10.1684/ejd.2020.3945. |
| ［50］ | Rademaker M, Agnew K, Andrews M，et al. Psoriasis in those planning a family, pregnant or breast⁃feeding. The Australasian Psoriasis Collaboration［J］. Australas J Dermatol, 2018,59（2）:86⁃100. doi: 10.1111/ajd.12641. |
| ［51］ | Owczarek W, Walecka I, Lesiak A, et al. The use of biological drugs in psoriasis patients prior to pregnancy, during pregnancy and lactation: a review of current clinical guidelines［J］. Postepy Dermatol Alergol, 2020,37（6）:821⁃830. doi: 10.5114/ada.2020. 102089. |
| ［52］ | Yeung J, Gooderham MJ, Grewal P, et al. Management of plaque psoriasis with biologic therapies in women of child⁃bearing potential consensus paper［J］. J Cutan Med Surg, 2020,24（1_suppl）:3S⁃14S. doi: 10.1177/1203475420928376. |
| ［53］ | Bronckers IM, Paller AS, van Geel MJ, et al. Psoriasis in children and adolescents: diagnosis, management and comorbidities［J］. Paediatr Drugs, 2015,17（5）:373⁃384. doi: 10. 1007/s40272⁃015⁃0137⁃1. |
| ［54］ | Gatti J, Lindstrom J A, Beitz J. Reconsideration of 2008 decision: Food and Drug Administration approval of etanercept for systemic treatment of moderate to severe pediatric psoriasis［J］. Pediatr Dermatol, 2018,35（5）:688⁃689. doi: 10.1111/pde. 13557. |
| ［55］ | Fabrizi G, Guerriero C, Pagliarello C. Etanercept in infants: suberythrodermic, recalcitrant psoriasis in a 22 month⁃old child successfully treated with etanercept［J］. Eur J Dermatol, 2007,17（3）:245. doi: 10.1684/ejd.2007.0159. |
| ［56］ | Zhang Z, Fan W, Yang G, et al. Risk of tuberculosis in patients treated with TNF⁃α antagonists: a systematic review and meta⁃analysis of randomised controlled trials［J］. BMJ Open, 2017,7（3）:e012567. doi: 10.1136/bmjopen⁃2016⁃012567. |
| ［57］ | 国家卫生健康委员会办公厅. 国家卫生健康委办公厅关于印发中国结核病预防控制工作技术规范（2020年版）的通知［EB/OL］. （2020⁃04⁃14）. https://www.sohu.com/a/387919909_771405. |
| ［58］ | Nogueira M, Warren RB, Torres T. Risk of tuberculosis reactivation with interleukin （IL）⁃17 and IL⁃23 inhibitors in psoriasis ⁃time for a paradigm change［J］. J Eur Acad Dermatol Venereol, 2021,35（4）:824⁃834. doi: 10.1111/jdv.16866. |
| ［59］ | Elewski BE, Baddley JW, Deodhar AA, et al. Association of secukinumab treatment with tuberculosis reactivation in patients with psoriasis, psoriatic arthritis, or ankylosing spondylitis［J］. JAMA Dermatol, 2021,157（1）:43⁃51. doi: 10.1001/jamadermatol. 2020.3257. |
| ［60］ | Shu D, Zhang Z, Zhou EY, et al. Is chemoprophylaxis necessary for all latent tuberculosis infection patients receiving IL⁃17 inhibitors? A cohort study［J］. Dermatol Ther, 2020,33（6）: e14512. doi: 10.1111/dth.14512. |
| ［61］ | 肿瘤坏死因子拮抗剂应用中结核病预防与管理专家建议组. 肿瘤坏死因子拮抗剂应用中结核病预防与管理专家共识［J］. 中华风湿病学杂志, 2013,17（8）:508⁃512. doi: 10.3760/cma.j.issn.1007⁃7480.2013.08.002. |
| ［62］ | Loomba R, Liang TJ. Hepatitis B reactivation associated with immune suppressive and biological modifier therapies: current concepts, management strategies, and future directions［J］. Gastroenterology, 2017,152（6）:1297⁃1309. doi: 10.1053/j.gastro. 2017.02.009 |
| ［63］ | Chiu HY, Hui RC, Huang YH, et al. Safety profile of secukinumab in treatment of patients with psoriasis and concurrent hepatitis B or C: a multicentric prospective cohort study［J］. Acta DermVenereol, 2018,98（9）:829⁃834. doi: 10. 2340/00015555⁃2989. |
| ［64］ | Vaengebjerg S, Skov L, Egeberg A, et al. Prevalence, incidence, and risk of cancer in patients with psoriasis and psoriatic arthritis: a systematic review and meta⁃analysis［J］. JAMA Dermatol, 2020,156（4）:421⁃429. doi: 10.1001/jamadermatol. 2020.0024. |
| ［65］ | Elmets CA, Leonardi CL, Davis D, et al. Joint AAD⁃NPF guidelines of care for the management and treatment of psoriasis with awareness and attention to comorbidities［J］. J Am Acad Dermatol, 2019,80（4）:1073⁃1113. doi: 10.1016/j.jaad.2018.11. 058. |
| ［66］ | Briukhovetska D, Dörr J, Endres S, et al. Interleukins in cancer: from biology to therapy［J］. Nat Rev Cancer, 2021,21（8）:481⁃499. doi: 10.1038/s41568⁃021⁃00363⁃z. |
| ［67］ | Zhao J, Chen X, Herjan T, et al. The role of interleukin⁃17 in tumor development and progression［J］. J Exp Med, 2020,217（1）:e20190297. doi: 10.1084/jem.20190297. |
| ［68］ | Yan J, Smyth MJ, Teng MWL. Interleukin （IL）⁃12 and IL⁃23 and their conflicting roles in cancer［J］. Cold Spring Harb Perspect Biol, 2018,10（7）:a028530. doi: 10.1101/cshperspect.a028530. |
| ［69］ | Peleva E, Exton LS, Kelley K, et al. Risk of cancer in patients with psoriasis on biological therapies: a systematic review［J］. Br J Dermatol, 2018,178（1）:103⁃113. doi: 10.1111/bjd.15830. |
| ［70］ | Plachouri KM, Georgiou S. Challenges in the treatment of psoriasis with biologics: vaccination, history of malignancy, human immunodeficiency virus （HIV） infection, and pediatric psoriasis［J］. Int J Dermatol, 2019,58（9）:1008⁃1013. doi: 10. 1111/ijd.14436. |
| ［71］ | Kamiya K, Komine M, Ohtsuki M. Biologics for psoriasis during the COVID⁃19 pandemic［J］. J Clin Med, 2021,10（7）:1390. doi: 10.3390/jcm10071390. |
| ［72］ | Smith CH, Jabbar⁃Lopez ZK, Yiu ZZ, et al. British Association of Dermatologists guidelines for biologic therapy for psoriasis 2017［J］. Br J Dermatol, 2017,177（3）:628⁃636. doi: 10.1111/bjd.15665. |
| ［73］ | Sacchelli L, Magnano M, Loi C, et al. The unforeseen during biotechnological therapy for moderate⁃to⁃severe psoriasis: how to manage pregnancy and breastfeeding, infections from Mycobacterium tuberculosis, hepatitis B virus, hepatitis C virus, and HIV, surgery, vaccinations, diagnosis of malignancy, and dose tapering［J］. Dermatol Ther, 2020,33（3）:e13411. doi: 10. 1111/dth.13411. |
| ［74］ | Ohtsuki M, Terui T, Ozawa A, et al. Japanese guidance for use of biologics for psoriasis （the 2013 version）［J］. J Dermatol, 2013, 40（9）:683⁃695. doi: 10.1111/1346⁃8138.12239. |
| ［75］ | Tsai TF, Hsieh TY, Chi CC, et al. Taiwan Rheumatology Association （TRA） and the Taiwanese Association for Psoriasis and Skin Immunology （TAPSI）. Recommendations for psoriatic arthritis management: a joint position paper of the Taiwan Rheumatology Association and the Taiwanese Association for Psoriasis and Skin Immunology［J］. J Formos Med Assoc, 2021, 120（3）:926⁃938. doi: 10.1016/j.jfma.2020.08.026. |
| [1] | 张宁, 李舒, 李敬. 免疫检查点抑制剂和靶向药物辅助治疗可切除黑素瘤疗效的网状Meta分析[J]. 中华皮肤科杂志, 2022, 0(4): 20200767-e20200767. |
| [2] | 王玥 严煜林. 寻常型银屑病患者171例阿维A治疗相关不良反应及停药原因分析[J]. 中华皮肤科杂志, 2022, 55(3): 242-245. |
| [3] | 李妍 李明 徐薇 李邻峰. 【开放获取】丙酸氟替卡松乳膏单独或联合卡泊三醇软膏治疗轻中度斑块状银屑病的随机自身对照研究[J]. 中华皮肤科杂志, 2022, 55(3): 260-263. |
| [4] | 王召阳 陈安薇 向欣 罗晓燕 徐子刚 王华 马琳. 基于两家儿童医院信息系统的儿童银屑病现状调查[J]. 中华皮肤科杂志, 2022, 55(3): 246-250. |
| [5] | 李浩, 王俐 韩宪伟 孙彤 苏芳 孙晓冬 韩莹 杨国玲 刘晓明 王凯波 . 糖尿病患者服用二肽基肽酶Ⅳ抑制剂后发生大疱性类天疱疮32例临床特征分析[J]. 中华皮肤科杂志, 2022, 55(3): 213-218. |
| [6] | 王晓雯 李若瑜. 白细胞介素17相关生物制剂治疗银屑病过程中浅部真菌感染的发生及应对策略[J]. 中华皮肤科杂志, 2022, 55(3): 272-275. |
| [7] | 《脓疱型银屑病诊疗中国专家共识（版）》编写委员会专家组. 脓疱型银屑病诊疗中国专家共识（2022版）[J]. 中华皮肤科杂志, 2022, 55(3): 187-195. |
| [8] | 王娟娟 陈容 季江 苏文星 魏钰倩 赵莹 尹兴平 苏玉华 施辛. 以精神行为异常为首发症状的67例神经梅毒患者回顾性分析[J]. 中华皮肤科杂志, 2022, 55(3): 231-234. |
| [9] | 张婷婷 朱凤仪 杨梅 张平 夏萍 周小勇. 司库奇尤单抗治疗红皮病型银屑病7例的临床疗效及安全性观察[J]. 中华皮肤科杂志, 2022, 0(2): 20210644-e20210644. |
| [10] | 温广东 冒丹丹 张原媛 窦沅青 赵培 吴晨雨 张建中. 【开放获取】度普利尤单抗治疗泛发性苔藓状淀粉样变1例国内首报[J]. 中华皮肤科杂志, 2022, 0(2): 20210694-e20210694. |
| [11] | 李赛, 薛华忠, 张树文, 蒋娟, 齐淑贞, 赵园园, 张津萍, 沙仲, 乐文静, 王碧伟, 赵诗轩, 朱小凤, 苏晓红. 多西环素-莫西沙星序贯疗法治疗生殖支原体尿道炎/宫颈炎的临床观察[J]. 中华皮肤科杂志, 2022, 0(2): 20210631-e20210631. |
| [12] | 焦晓燕, 尹光文, 阴亚坤, 李冬芹. 妊娠期、围生期带状疱疹25例临床分析[J]. 中华皮肤科杂志, 2022, 0(2): 20210384-e20210384. |
| [13] | 王佳绮, 王平, 李刘雨, 樊奇敏, 朱蒙燕, 王燕清, 周鸿宇, 沈宏, 许爱娥. 皮肤色素减退性淋巴增殖性疾病41例临床病理分析[J]. 中华皮肤科杂志, 2022, 55(2): 110-115. |
| [14] | 欧敏, 颜韵灵, 郑宝庆, 王晓华. 银屑病与肥胖相关性的研究进展[J]. 中华皮肤科杂志, 2022, 55(2): 181-184. |
| [15] | 包诗杰, 程杨, 晏莹, 范昉, 高婷婷, 冯小兰, 郑亮, 雷卫, 黄琴斯, 张伟明, 周小勇. 人免疫球蛋白和重组人Ⅱ型肿瘤坏死因子受体-抗体融合蛋白治疗中毒性表皮坏死松解症的对比研究[J]. 中华皮肤科杂志, 2022, 55(2): 153-156. |
|
